Immunogenomic predictors of outcomes in patients with locally advanced cervical cancer treated with immunotherapy and chemoradiation
接受免疫治疗和放化疗的局部晚期宫颈癌患者结果的免疫基因组预测因子
基本信息
- 批准号:10908093
- 负责人:
- 金额:$ 59.54万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-07-01 至 2026-06-30
- 项目状态:未结题
- 来源:
- 关键词:AddressAffectAftercareAntigen-Presenting CellsBioinformaticsBiological AssayBiological MarkersBiopsyBloodBlood specimenCancer PatientCellsCessation of lifeChemotherapy and/or radiationCisplatinClinicalClinical TrialsClonalityCollectionCombination Drug TherapyCombination immunotherapyDNADNA copy numberDataDiseaseDisease MarkerDisease-Free SurvivalDrug TargetingEarly identificationEvolutionExhibitsFinancial HardshipFluorescence MicroscopyFreezingFundingGeneticGenomicsGoalsHead and Neck CancerHuman PapillomavirusHuman papilloma virus infectionImmunofluorescence MicroscopyImmunogenomicsImmunotherapyIn complete remissionKnowledgeMaintenanceMaintenance TherapyMalignant neoplasm of cervix uteriMeasuresMetastatic Neoplasm to Lymph NodesMolecular ProfilingMorbidity - disease rateOutcomePD-1 inhibitorsPDL1 inhibitorsPET/CT scanParaaorticPathologicPatient SelectionPatient-Focused OutcomesPatientsPeripheralPhenotypePlasmaPositron-Emission TomographyPredictive ValuePrognosisRadiationRadiation therapyRandomizedRecurrenceRelapseRiskSourceSpecimenT cell receptor repertoire sequencingT-Cell ActivationT-Cell ProliferationT-Cell ReceptorT-LymphocyteT-cell receptor repertoireTechniquesTissuesToxic effectTumor TissueUnited StatesViralWomananti-tumor immune responsearmbiomarker identificationburden of illnesschemoradiationdigitaldraining lymph nodeexperiencefollow-uphigh riskimmune checkpoint blockadeimmunotherapy clinical trialsimprovedmortalityneoplastic cellnovel therapeutic interventionoutcome predictionpartial responsepatient stratificationpembrolizumabperipheral bloodpredicting responsepredictive markerprogrammed cell death ligand 1programmed cell death protein 1prospectiveradiological imagingresponserisk stratificationspatial relationshipstandard of caretreatment responsetumortumor microenvironmenttumor-immune system interactionsuptake
项目摘要
Project Summary/Abstract
Locally advanced cervical cancer (LACC) associated with human papillomavirus (HPV) infection continues to
be a significant source of morbidity and mortality in the US and globally. In particular, patients with evidence
of metastases to lymph nodes have a dismal 3-year overall survival of 39%, despite treatment with the
current standard of care of chemotherapy combined with radiation (CRT). There is thus a critical need
to develop new therapeutic strategies for patients with high-risk LACC. Combinations of CRT with
immune checkpoint blockade (ICB) drugs targeting PD-L1 (durvalumab) or PD-1 (pembrolizumab) are being
studied in global prospective trials CALLA and KEYNOTE A18, respectively. Unfortunately, the results of the
CALLA trial failed to demonstrate substantial improvement in 24-month survival with addition of durvalumab,
highlighting several critical knowledge gaps in combination of CRT and ICB in LACC. First, optimal sequencing
of CRT and ICB is unknown, and there are clear concerns that concurrent initiation of CRT and ICB carries a
potential to kill activated proliferating T cells in tumors and tumor-draining lymph nodes, leading to tolerance.
Second, predictors of long-term outcomes for the patients treated with ICB and CRT are unknown. In this
application, our key study objectives are to examine the evolution of blood and tumor
microenvironment (TME) immune parameters in response to differential ICB-CRT sequencing and to
establish the predictors of long-term outcomes. To achieve these goals, we conducted and completed an
NCI-sponsored clinical trial of PD-L1 inhibitor atezolizumab in combination with CRT in patients with high-risk
LACC, randomizing patients to atezolizumab administration prior to and concurrent with CRT vs. concurrent
with CRT in 36 patients. The study incorporated comprehensive collection of pre- and on-treatment tumor
biopsies and blood and PET scans that will enable us to address the knowledge gaps above. In Aim 1 we will
determine how the tumor immune microenvironment evolves as a function of differential immunotherapy and
CRT sequencing. By using multi-parameter fluorescence microscopy, we will determine how activation of T
cells and their interaction with other cells in the tumors change in response to therapy and how these changes
predict long term outcomes. In Aim 2, we will take advantage of T cell receptor (TCR) repertoire sequencing as
well as advanced bioinformatics techniques to evaluate how evolution of T cells in tumors and peripheral blood
could serve as an indicator of anti-tumor immune response and long-term outcomes. In Aim 3 we will establish
radiographic and blood biomarkers as predictors of outcomes in high-risk LACC patients by examining blood
HPV DNA and post-treatment PET-CT as markers of disease burden pre- and post-therapy. Identification of
early biomarkers predictive of outcomes will be critical for risk-stratification of patients with LACC in
order to guide patient selection for clinical trials or maintenance therapy, while minimizing the
potential clinical toxicities and financial burden in patients at low risk for recurrence.
项目总结/摘要
与人乳头瘤病毒(HPV)感染相关的局部晚期宫颈癌(LACC)持续存在,
是美国和全球发病率和死亡率的重要来源。尤其是有证据表明
的淋巴结转移患者的3年总生存率为39%,
目前的标准治疗化疗联合放疗(CRT)。因此,迫切需要
为高危LACC患者开发新的治疗策略。CRT与
靶向PD-L1(durvalumab)或PD-1(pembrolizumab)的免疫检查点阻断(ICB)药物正在
分别在全球前瞻性试验CALLA和KEYNOTE A18中进行了研究。不幸的是,
CALLA试验未能证明添加durvalumab后24个月生存率的实质性改善,
强调LACC中CRT和ICB组合的几个关键知识差距。第一,最优排序
CRT和ICB的并发症是未知的,并且有明确的担忧,即CRT和ICB的同时启动会导致
杀伤肿瘤和肿瘤引流淋巴结中活化增殖T细胞的潜力,导致耐受。
其次,ICB和CRT治疗患者的长期结局预测因素尚不清楚。在这
应用,我们的主要研究目标是检查血液和肿瘤的演变
微环境(TME)免疫参数响应差异ICB-CRT测序和
建立长期结果的预测指标。为了实现这些目标,我们进行并完成了一项
NCI申办的PD-L1抑制剂atezolizumab联合CRT治疗高危患者的临床试验
LACC,将患者随机分配至在CRT之前和同时接受atezolizumab给药vs.同时
CRT治疗36例。该研究包括全面收集治疗前和治疗中的肿瘤
活组织检查、血液和PET扫描,这将使我们能够解决上述知识差距。在目标1中,
确定肿瘤免疫微环境如何作为差异免疫治疗的函数演变,
CRT序列。通过使用多参数荧光显微镜,我们将确定如何激活T
细胞及其与肿瘤中其他细胞的相互作用对治疗的反应发生变化,
预测长期结果。在目标2中,我们将利用T细胞受体(TCR)库测序,
以及先进的生物信息学技术来评估肿瘤和外周血中T细胞的进化
可以作为抗肿瘤免疫反应和长期结果的指标。在目标3中,我们将建立
影像学和血液生物标志物作为高风险LACC患者预后的预测因子
HPV DNA和治疗后PET-CT作为治疗前和治疗后疾病负担的标志物。鉴定
预测预后的早期生物标志物对于LACC患者的风险分层至关重要,
为了指导临床试验或维持治疗的患者选择,同时最大限度地减少
潜在的临床毒性和经济负担的患者在低风险的复发。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Dmitriy Zamarin其他文献
Dmitriy Zamarin的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Dmitriy Zamarin', 18)}}的其他基金
Immunogenomic predictors of outcomes in patients with locally advanced cervical cancer treated with immunotherapy and chemoradiation
接受免疫治疗和放化疗的局部晚期宫颈癌患者结果的免疫基因组预测因子
- 批准号:
10733542 - 财政年份:2023
- 资助金额:
$ 59.54万 - 项目类别:
POTENTIATION OF ANTI-TUMOR IMMUNITY BY ONCOLYTIC VIRUS IN SITU VACCINATION
溶瘤病毒原位疫苗接种增强抗肿瘤免疫力
- 批准号:
10908106 - 财政年份:2023
- 资助金额:
$ 59.54万 - 项目类别:
POTENTIATION OF ANTI-TUMOR IMMUNITY BY ONCOLYTIC VIRUS IN SITU VACCINATION
溶瘤病毒原位疫苗接种增强抗肿瘤免疫力
- 批准号:
10584115 - 财政年份:2023
- 资助金额:
$ 59.54万 - 项目类别:
相似海外基金
How Does Particle Material Properties Insoluble and Partially Soluble Affect Sensory Perception Of Fat based Products
不溶性和部分可溶的颗粒材料特性如何影响脂肪基产品的感官知觉
- 批准号:
BB/Z514391/1 - 财政年份:2024
- 资助金额:
$ 59.54万 - 项目类别:
Training Grant
BRC-BIO: Establishing Astrangia poculata as a study system to understand how multi-partner symbiotic interactions affect pathogen response in cnidarians
BRC-BIO:建立 Astrangia poculata 作为研究系统,以了解多伙伴共生相互作用如何影响刺胞动物的病原体反应
- 批准号:
2312555 - 财政年份:2024
- 资助金额:
$ 59.54万 - 项目类别:
Standard Grant
RII Track-4:NSF: From the Ground Up to the Air Above Coastal Dunes: How Groundwater and Evaporation Affect the Mechanism of Wind Erosion
RII Track-4:NSF:从地面到沿海沙丘上方的空气:地下水和蒸发如何影响风蚀机制
- 批准号:
2327346 - 财政年份:2024
- 资助金额:
$ 59.54万 - 项目类别:
Standard Grant
Graduating in Austerity: Do Welfare Cuts Affect the Career Path of University Students?
紧缩毕业:福利削减会影响大学生的职业道路吗?
- 批准号:
ES/Z502595/1 - 财政年份:2024
- 资助金额:
$ 59.54万 - 项目类别:
Fellowship
感性個人差指標 Affect-X の構築とビスポークAIサービスの基盤確立
建立个人敏感度指数 Affect-X 并为定制人工智能服务奠定基础
- 批准号:
23K24936 - 财政年份:2024
- 资助金额:
$ 59.54万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Insecure lives and the policy disconnect: How multiple insecurities affect Levelling Up and what joined-up policy can do to help
不安全的生活和政策脱节:多种不安全因素如何影响升级以及联合政策可以提供哪些帮助
- 批准号:
ES/Z000149/1 - 财政年份:2024
- 资助金额:
$ 59.54万 - 项目类别:
Research Grant
How does metal binding affect the function of proteins targeted by a devastating pathogen of cereal crops?
金属结合如何影响谷类作物毁灭性病原体靶向的蛋白质的功能?
- 批准号:
2901648 - 财政年份:2024
- 资助金额:
$ 59.54万 - 项目类别:
Studentship
Investigating how double-negative T cells affect anti-leukemic and GvHD-inducing activities of conventional T cells
研究双阴性 T 细胞如何影响传统 T 细胞的抗白血病和 GvHD 诱导活性
- 批准号:
488039 - 财政年份:2023
- 资助金额:
$ 59.54万 - 项目类别:
Operating Grants
New Tendencies of French Film Theory: Representation, Body, Affect
法国电影理论新动向:再现、身体、情感
- 批准号:
23K00129 - 财政年份:2023
- 资助金额:
$ 59.54万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
The Protruding Void: Mystical Affect in Samuel Beckett's Prose
突出的虚空:塞缪尔·贝克特散文中的神秘影响
- 批准号:
2883985 - 财政年份:2023
- 资助金额:
$ 59.54万 - 项目类别:
Studentship